Navigation Links
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
Date:10/24/2008

ESSEX, United Kingdom, Oct. 24 /PRNewswire-FirstCall/ -- Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo. This result in the primary endpoint of the study is both clinically and statistically highly significant.

A further primary endpoint showed a reduction in the number of migraine headache days. This reduction did not reach statistical significance, probably owing to the small number of patients participating in the trial and, it is thought, because some of the patients suffered a type of migraine aura that is not followed by headache.

The results also showed statistically significant effects on some of the secondary endpoints including the number of attacks of migraine headache and the number of auras followed by any headache. All secondary endpoints were numerically in favor of tonabersat compared with placebo.

Migraine with aura affects around 30 percent of migraine sufferers and is a type of migraine in which the headache is preceded by symptoms such as visual disturbances and abnormalities of speech and hearing. These aura symptoms are generally recognized as being difficult to treat with existing medications.

A total of 31 patients completed the Phase II trial, which was conducted at the Danish Headache Center at Copenhagen's Glostrup University Hospital. The principal investigator in the trial was Professor Jes Olesen, the Danish Headache Center's Director and one of the world's leading authorities on headache.

Under the trial's cross-over design, patients took either tonabersat or placebo once a day for a three-month period after which the treatment regimen was reversed such that those initially on tonabersat received placebo and vice versa. The tonabersat dosage was 20mg a day for the first two weeks, increasing to 40mg a day for the subsequent 10 weeks.

In line with previous experience, tonabersat was generally well tolerated by patients.

It is expected that the detailed results of the trial will be published by Professor Olesen's group in a peer-reviewed article in a leading international journal.

Tonabersat is the leading compound in an exciting new class of selective drugs known as neuronal gap junction blockers, which offer the potential to prevent the onset of migraine as a preferred alternative to acute treatment.

Minster is currently conducting the 500 patient TEMPUS trial of tonabersat in prevention of migraine in the US and Canada. This Phase IIb trial is fully enrolled and results are expected in the first quarter of 2009.

"This is the first time for more than 30 years that a drug designed specifically for migraine prevention shows significant efficacy. There is a huge need for better preventives, so these trial results are very encouraging. It is clear that tonabersat has very real potential in the preventive treatment of migraine," said Professor Jes Olesen, the principal investigator in the trial and Director of the Danish Headache Center.

"The very positive results from this Phase II trial in migraine with aura reinforce our confidence in the potential of tonabersat. These results represent a significant advance in our overall program, which we are well funded to deliver, to establish tonabersat as the treatment of choice for prevention of migraine attacks. We look forward to the results of the TEMPUS trial of tonabersat in the wider migraine population, which is on track to report out in Q1 2009," said Paul Sharpe, Minster Pharmaceuticals' Chief Executive Officer.

Notes for editors:

About Minster Pharmaceuticals plc

Minster Pharmaceuticals is a drug development company focused on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in schizophrenia. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.

Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia.

Minster's near-term focus is on the development and commercialization of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of creating a substantial and highly efficient drug development enterprise focused on the central nervous system.

Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit http://www.minsterpharma.com .


'/>"/>
SOURCE Minster Pharmaceuticals plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
2. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
3. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
4. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
5. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
6. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
10. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
Breaking Medicine Technology:
(Date:9/25/2017)... PA (PRWEB) , ... September 25, 2017 , ... PITTSBURGH...An ... way to update patient charts in hospitals and medical facilities, so he invented the ... access and update patient charts. In doing so, it offers an improved alternative to ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... supporting clinical research, today announces that 30 of its domain experts will ... development lifecycle at upcoming industry conferences and webinars. Drawing on broad and ...
(Date:9/25/2017)... Korea (PRWEB) , ... September 25, 2017 , ... Earlypicker ... looking for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping ... for a company that’s already well-known for the great offerings that allow Koreans everywhere ...
(Date:9/25/2017)... ... , ... “The Majestic Unicorn”: a poignant book that describes what happened ... creation of published author, Dayna Chantel, an artist and a writer. , Chantel shares, ... aboard the cypress ark-vessel. Male and female, no matter what species, they were chosen ...
(Date:9/25/2017)... ... ... Emerald Ash Borers kill Ash trees in as little as 1-3 years. The ... video by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street ... showing signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
Breaking Medicine News(10 mins):